BiotechTube

Octreotide acetate

ApprovedTerminated
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Acromegaly

Conditions

Acromegaly

Trial Timeline

Mar 1, 2003 → —

NCT ID
NCT00242541

About Octreotide acetate

Octreotide acetate is a approved stage product being developed by Novartis for Acromegaly. The current trial status is terminated. This product is registered under clinical trial identifier NCT00242541. Target conditions include Acromegaly.

What happened to similar drugs?

12 of 20 similar drugs in Acromegaly were approved

Approved (12) Terminated (0) Active (8)
🔄Pasireotide LARNovartisPhase 3
🔄Octreotide acetate 30 mg suspensionNovartisPhase 3
✅Sandostatin LAR + pegvisomant + cabergolineNovartisApproved
✅Octreotide acetate and cabergoline/Octrotide and SomavertNovartisApproved
✅Sandostatin LARNovartisApproved
🔄Pasireotide + OctreotideNovartisPhase 3
✅Sandostatin (Octreotide Acetate)NovartisApproved

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00242541ApprovedTerminated

Competing Products

20 competing products in Acromegaly

See all competitors
ProductCompanyStageHype Score
AlesseNovartisPhase 2
31
ONO-5788 + ONO-5788 Placebo + OctreotideOno PharmaceuticalPhase 1
21
ONO-5788 + [14C]-ONO-5788Ono PharmaceuticalPhase 1
29
Pasireotide LARNovartisPhase 3
40
Octreotide acetate 30 mg suspensionNovartisPhase 3
40
Pasireotide long acting release formulationNovartisPre-clinical
26
Sandostatin LAR + pegvisomant + cabergolineNovartisApproved
43
Octreotide acetate and cabergoline/Octrotide and SomavertNovartisApproved
43
Sandostatin LARNovartisApproved
43
Pasireotide + OctreotideNovartisPhase 3
40
Sandostatin (Octreotide Acetate)NovartisApproved
39
octreotide FluidCrystal® injection depotNovartisPhase 2
35
Octreotide LARNovartisPhase 3
40
Octreotide LARNovartisPhase 3
40
PasireotideNovartisPhase 2
35
Pasireotide LAR 60 mg + PegvisomantNovartisApproved
39
OctreotideNovartisApproved
43
Octreotide LAR 30 MG InjectionNovartisApproved
43
Pasireotide LARNovartisPhase 2
35
Pasireotide (SOM230), Octreotide (Sandostatin)NovartisPhase 2
35